Vivani Medical, Inc.
VANIHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframeVivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. At a $122.2M market cap, Vivani Medical, Inc. ranks as a micro-cap company within healthcare. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases.
Market Cap
$122.2M
Beta
3.28
P/E (TTM)
—
P/E (Fwd)
-3.87
EPS (TTM)
$-0.36
EPS (Fwd)
$-0.35
ROE
-220.4%
ROA
-48.5%
Cash
$19.9M
Total Debt
$17.9M
Free CF
-$16.8M
52W Change
22.1%
Annual Financials
Cash vs Debt
Where VANI stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, VANI finished 12.70% above its 150-day moving average ($1.26) and 10.94% above its 200-day moving average ($1.28). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VANI overbought or oversold?
At the September 3, 2026 close, VANI's RSI(14) was 57.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $19.9M in cash and $17.9M in debt, VANI maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$16.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -220.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Vivani Medical, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Vivani Medical, Inc.'s trajectory.